November 24, 2016 / 7:21 AM / 14 days ago

BRIEF-Inventiva Completes Patient Visits For Phase IIb Clinical Study With Lanifibranor

March 17 (Reuters) - INVENTIVA SA:

* ANNOUNCES COMPLETION OF PATIENT VISITS FOR ITS PHASE IIB CLINICAL STUDY WITH LANIFIBRANOR IN NASH

* ALL BIOPSIES HAVE BEEN ANALYSED BY CENTRAL HEPATOLOGIST AND PUBLICATION OF STUDY HEAD-LINE RESULTS IS PLANNED IN JUNE 2020, IN LINE WITH COMPANY’S EXPECTATIONS

* LAST PATIENT BIOPSY WAS PERFORMED IN FEBRUARY AND LAST SAFETY VISIT TOOK PLACE IN UNITED STATES ON MARCH 16, 2020

* WE ARE LOOKING FORWARD TO PUBLISHING THE HEAD-LINE RESULTS IN THE NEXT FEW MONTHS, WHICH, IF POSITIVE, WILL SUPPORT THE LAUNCH OF THE PIVOTAL PHASE III STUDY WITH LANIFIBRANOR - COFOUNDER Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below